Latest news

• Alnylam gains key NICE approval for Onpattro

  Marketed by Ionis subsidiary Akcea Therapeutics, Tegsedi stole a march over Onpattro when it gained NICE approval in April, but now Alnylam has a matching recommendation from England’s cost watchdog.

• Akcea steals march on Alnylam with NICE approval

  Advantage to Tegsedi over Onpattro. NICE has recommended Akcea Therapeutics’ rare disease treatment Tegsedi (inotersen), after the company improved its price offer. ... Richard A. Jones, SVP Head of Europe for Akcea Therapeutics. “hATTR amyloidosis

• Novartis in-licenses Akcea’s novel cardiovascular therapy

  Lp(a) targeting therapy could treat millions. Novartis has acquired rights to a novel cardiovascular drug from Akcea Therapeutics, which it says to could be a first-in-class and treat ... This adds to an earlier $225m payment in cash and equity

• Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding

  FDA surprises Akcea and Ionis with rejection of Waylivra. Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, has been knocked back by a surprise rejection via a Complete Response Letter (CRL) from ... Paula Soteropoulos. Akcea’s CEO Paula

• Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

  Meanwhile Ionis and its subsidiary Akcea Therapeutics also got the thumbs up for their rare disease treatment Tegsedi(inotersen) – a decision which could see it approved in Europe before the US,